Big Pharma pursues epigenetics for cancer breakthroughs

Big Pharma companies like GlaxoSmithKline, Eli Lilly and Novartis are among the drugmakers pursuing new cancer treatments based on epigenetics--an approach that aims to reprogram abnormal DNA that causes cells to become cancerous. Epigenetics is already used in oncology drugs that treat certain blood-cancer disorders, but the real test will be to see whether it can also be applied to solid tumor cancers. Piece

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.